Clinical trial · Observational
Patient Journey in Advanced Gynecologic Cancers
Patient Journey in Conventional Therapy for Primarily Treated Advanced Gynecologic Cancers in China
NCT07015593CI-TRIAL-00090850not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Genital Neoplasms, Female | Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- experimental group
- description
- 780 patients for interview
- interventionNames
- Other: interview
Primary outcomes (3)
- measure
- Treatment decision making
- timeFrame
- 1 day. At the time of the interview.
- description
- 1. Information seeking in treatment decision 2. Treatment decision making factors 3. Clinical trial awareness
- measure
- Initial treatment experiences
- timeFrame
- 1 day. At the time of the interview.
- description
- 1. Influence of treatment on daily life and work 2. Information and education during treatment 3. Coordination of care 4. Overall impression on care received and doctor/nurses' availability
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or older * Newly diagnosed stage III or IV CC or EC * Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis. * Told by their physician that their disease is stable. * Patients must have informed consent form (ICF) signed for the study. Exclusion Criteria: * Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Previously participated in or participating in a clinical trial. * Patients who received another line of therapy after initial therapy. * Unable or unwilling to provide informed consent. * Not fluent in local language. * Indicates or exhibits hearing difficulties, which would make a conversation challenging.
References
Publications (0)
Data not yet available
No reference posted for this study.